Several studies has described that significant molecular biomarkers in GBM were identified as prognostic or therapeutic factors, such as O6-methylguanine-DNA methyltransferase (MGMT), epidermal growth factor receptor (EGFR) and isocitrate dehydrogenase (IDH) [7, 8]. This evidence concerns the gene IDH1 and glioblastoma.